Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +3.76%41 Current Ratio is 2.22 as of Jun. 2026, which is 113% above its 10-year median of 1.04. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 52.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Interpace Biosciences's current ratio for the quarter that ended in Jun. 2026 was 2.22.
Interpace Biosciences has a current ratio of 2.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for Interpace Biosciences's Current Ratio or its related term are showing as below:
IDXG'
s Current Ratio Range Over the Past 10 Years
Min: 0.26 Med: 1.04 Max: 2.61
Current: 2.22
During the past 13 years, Interpace Biosciences's highest Current Ratio was 2.61. The lowest was 0.26. And the median was 1.04.
IDXG's Current Ratio is ranked better than 52.83% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs IDXG: 2.22
Interpace Biosciences (OTCPK:IDXG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Interpace Biosciences Current Ratio Related Terms
Interpace Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDXG vs PRPO, ADVB, BIOQ: Current Ratio Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a Current Ratio of 2.22 as of Jun. 2026. This is 113% above median its historical median of 1.04. Over the past decade, Interpace Biosciences' Current Ratio has ranged from 0.26 to 2.61. According to the industry distribution chart, Interpace Biosciences ranks #100 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 47.2%.
Is Interpace Biosciences' Current Ratio too high?
Interpace Biosciences' current Current Ratio of 2.22 is 113% above median its 10-year median of 1.04. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 2.61. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Interpace Biosciences' value of 2.22 is 5.7% above this industry median. Based on the distribution chart, Interpace Biosciences ranks #100 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Current Ratio compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #100 out of 212 companies for Current Ratio. This puts Interpace Biosciences in the upper half of its industry. The industry median Current Ratio is 2.10. Interpace Biosciences' value of 2.22 is 5.7% above this benchmark. Historically, Interpace Biosciences' own Current Ratio has ranged from 0.26 to 2.61 over the past decade. While the company's 10-year median is 1.04 vs. the industry median of 2.10, Interpace Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Current Ratio of 2.22 is 5.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Current Ratio is 2.22, which is 113% above median its own 10-year median of 1.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.63 — trading 714.5% above its estimated fair value. The current Current Ratio is 2.22, which is 113% above median its 10-year median of 1.04 and 5.7% above the Medical Diagnostics & Research industry median of 2.10. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Current Ratio is 2.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.63 is trading 714.5% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
Current Ratio: 2.22 (113% above median its 10-year median of 1.04)
GF Value™: $0.20 vs. price of $1.63 (714.5% above fair value)
Industry Position: 5.7% above the Medical Diagnostics & Research median (#100 of 212)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
